Stefan H, Hubbertz L, Peglau I, Berrouschot J, Kasper B, Schreiner A, Krimmer J, Schauble B
Epilepsy Center, University of Erlangen, Germany.
Acta Neurol Scand. 2008 Sep;118(3):164-74. doi: 10.1111/j.1600-0404.2008.01018.x. Epub 2008 Mar 31.
To explore effectiveness, tolerability and quality of life in elderly patients with epilepsy treated with topiramate.
One year, open-label, flexible-dosing clinical trial.
One hundred and seven patients (mean age 69 years, 53% men) were studied during 273 +/- 141 days. The average final dose in monotherapy was 98 mg/day vs 153 mg/day in adjunctive treatment. Mean monthly cumulative seizure frequency decreased from 3.7 +/- 15 to 1.6 +/- 7.7 (n = 101, P < 0.0001), 78% of patients with seizures at baseline (n = 102) achieved at least 50% reduction in seizure frequency, 44% were seizure-free throughout the trial. Total scores on the quality of life in epilepsy inventory (QOLIE-31) improved from 57 +/- 17 to 68 +/- 18 (n = 64, P < 0.0001). The most frequently reported adverse events included convulsions, dizziness and tiredness.
Elderly patients treated with topiramate showed marked reductions in seizures, good tolerability and significant improvements in several aspects of quality of life.
探讨托吡酯治疗老年癫痫患者的有效性、耐受性及生活质量。
为期一年的开放标签、灵活剂量临床试验。
107例患者（平均年龄69岁，53%为男性）接受了273±141天的研究。单药治疗的平均最终剂量为98毫克/天，辅助治疗为153毫克/天。平均每月累积癫痫发作频率从3.7±15降至1.6±7.7（n = 101，P < 0.0001），78%的基线时有癫痫发作的患者（n = 102）癫痫发作频率至少降低了50%，44%的患者在整个试验期间无癫痫发作。癫痫生活质量量表（QOLIE - 31）的总分从57±17提高到68±18（n = 64，P < 0.0001）。最常报告的不良事件包括惊厥、头晕和疲劳。
接受托吡酯治疗的老年患者癫痫发作明显减少，耐受性良好，生活质量的多个方面有显著改善。
